|
Key figures – 2nd quarter 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
€ million |
Pharma-ceuticals |
Chemicals |
Corporate |
Total |
Change |
|
Total revenues |
1,598.2 |
957.2 |
– |
2,555.4 |
15.7 |
|
Gross margin |
1,266.5 |
528.4 |
– |
1,795.0 |
6.2 |
|
Research and development |
–307.1 |
–62.0 |
– |
–369.1 |
9.0 |
|
Operating result |
–137.3 |
150.6 |
–24.7 |
–11.4 |
– |
|
Exceptional items |
5.8 |
0.4 |
–17.3 |
–11.1 |
– |
|
Earnings before interest and tax (EBIT) |
–131.5 |
151.0 |
–42.0 |
–22.5 |
– |
|
EBIT before depreciation and amortization (EBITDA) |
349.3 |
256.0 |
–40.8 |
564.5 |
0.8 |
|
Return on sales in % |
–8.6 |
15.7 |
– |
–0.4 |
|
|
Free cash flow |
151.9 |
213.0 |
–111.7 |
253.2 |
–28.9 |
|
Underlying free cash flow |
146.6 |
223.1 |
–111.7 |
258.1 |
–28.3 |
|
Underlying free cash flow on revenues (FCR) in % |
9.2 |
23.3 |
– |
10.1 |
|
